The website of the Clinical Services Journal

25,000 people to benefit after NICE recommends new ulcerative colitis treatment

Thousands of people could be set to benefit after NICE recommended a new one-a-day pill as an option for treating severe ulcerative colitis.

NICE’s final guidance on etrasimod (also known as Velsipity and made by Pfizer) was published on the same day that the treatment was granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA). 

Just over 25,000 people in England are eligible to receive the new treatment, which was evaluated using a simpler technology appraisal process. As a result, the final guidance was available up to eight weeks faster than would have been the case under standard process. 

Etrasimod is recommended for people aged 16 and over with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or biological treatment.   

Ulcerative colitis is a long-term disease affecting the colon and rectum and can cause recurring diarrhoea, arthritis, and osteoporosis. The treatment helps reduce inflammation in the colon by helping to control the level of immune cells in the blood.  

Clinical trial evidence shows that etrasimod is more effective than placebo for treating moderately to severely active ulcerative colitis. Indirect comparisons suggest that it is likely to work better than adalimumab (an immunotherapy treatment) and may be similarly effective to other usual treatments for moderately to severely active ulcerative colitis.  

Helen Knight, director of medicines evaluation at NICE, said: “Severe ulcerative colitis is a debilitating lifelong condition; etrasimod provides a new convenient and effective treatment option that will make a positive difference for thousands of people."

It is estimated that around 300,000 people across the UK have been diagnosed with ulcerative colitis. The condition can develop at any age but is most often diagnosed in people between 15 and 25-years-old.   

The company has a confidential commercial arrangement in place which makes etrasimod available to the NHS with a discount. Read the full final guidance recommending etrasimod for treating moderately to severely active ulcerative colitis on the NICE website. 

Upcoming Events

Infection Prevention & Control

National Conference Centre, Birmingham
23rd - 24th April 2024

ESGE Days 2024, Symposium – ‘Elevating Endoscopy: Inspiring Progress and Innovation’

Estrel Congress Center (room 15), Berlin, Germany
25th April 2024, 16:30 – 17:30 CEST

National DERS and SMART pump conference

BCEC, Birmingham
29th April 2024

Theatres & Decontamination Conference 2024

Coventry Building Society Arena
16th May 2024

The AfPP Roadshow - Birmingham

Millennium Point, Birmingham
18th May 2024

BAUN Summer Educational Event – Essential Urology Skills

Crowne Plaza, Newcastle Stephenson Quarter
6th June 2024

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Upcoming Events

Infection Prevention & Control

National Conference Centre, Birmingham
23rd - 24th April 2024

ESGE Days 2024, Symposium – ‘Elevating Endoscopy: Inspiring Progress and Innovation’

Estrel Congress Center (room 15), Berlin, Germany
25th April 2024, 16:30 – 17:30 CEST

National DERS and SMART pump conference

BCEC, Birmingham
29th April 2024

Theatres & Decontamination Conference 2024

Coventry Building Society Arena
16th May 2024

The AfPP Roadshow - Birmingham

Millennium Point, Birmingham
18th May 2024

BAUN Summer Educational Event – Essential Urology Skills

Crowne Plaza, Newcastle Stephenson Quarter
6th June 2024

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025